Todd Levine

Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello.

Phoenix Neurological Associates Ltd. engages in treating patients with neurologic diseases. It specializes in alzheimers, amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, epilepsy, guillain barre syndrome, headache, inclusion body myositis, movement disorders, multiple sclerosis and muscular dystrophy. The company is headquartered in Phoenix, AZ.

Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello.

Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello.

Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello.